Abstract: A method for facilitating automated application performance monitoring threshold management through deep learning model is provided. The method includes retrieving, via an application programming interface, raw data that correspond to an application, the raw data including application performance data; generating data frames based on the raw data, the data frames relating to a multi-dimensional data structure; converting the data frames into a model; developing an error function that optimizes a regression coefficient; training the model by using the error function; and determining, by using the trained model, forecasted threshold values that relate to application performance metrics for the application.

Abstract: An approach is provided for optimizing data fetching. A query employing a method to fetch data from a JSON document is received. An amount of time required to execute the query and a number of nested layers in a traversal of the JSON document required to fetch the data are determined. Based on the amount of time and the number of nested layers, a cost associated with an execution of the query is calculated. The cost is determined to exceed a threshold value. Responsive to the determination that the cost exceeds the threshold value and using historical query patterns and historical query execution times, a schema of the JSON document is re-designed. The data is fetched from the JSON document using the re-designed schema.

Abstract: An approach is provided for optimizing data fetching. A query employing a method to fetch data from a JSON document is received. An amount of time required to execute the query and a number of nested layers in a traversal of the JSON document required to fetch the data are determined. Based on the amount of time and the number of nested layers, a cost associated with an execution of the query is calculated. The cost is determined to exceed a threshold value. Responsive to the determination that the cost exceeds the threshold value and using historical query patterns and historical query execution times, a schema of the JSON document is re-designed. The data is fetched from the JSON document using the re-designed schema.

Abstract: The present invention is directed to a composition comprising (a) cabazitaxel and (b) sulfobutyl ether beta cyclodextrin. Such composition exhibits unexpectedly desirable stability in aqueous media, permitting therapeutic dosages of the drug to be administered without the use of either ethanol or surfactants.

Abstract: A view schema is generated from a view definition, wherein the view schema includes one or more relational views that are created by translating one or more object queries in the view definition into one or more relational queries. A report design schema is generated from the view definition by: creating one or more report tables that correspond to the one or more relational views of the view schema and extending the one or more report tables with one or more primary key constraints and one or more foreign key constraints. A reporting model is generated by reverse engineering the report design schema, wherein the reporting model includes the one or more primary key constraints and the one or more foreign key constraints. A report is generated using the reporting model, wherein the report includes the one or more primary key constraints and the one or more foreign key constraints.

Abstract: A view schema is generated from a view definition, wherein the view schema includes one or more relational views that are created by translating one or more object queries in the view definition into one or more relational queries. A report design schema is generated from the view definition by: creating one or more report tables that correspond to the one or more relational views of the view schema and extending the one or more report tables with one or more primary key constraints and one or more foreign key constraints. A reporting model is generated by reverse engineering the report design schema, wherein the reporting model includes the one or more primary key constraints and the one or more foreign key constraints. A report is generated using the reporting model, wherein the report includes the one or more primary key constraints and the one or more foreign key constraints.

Abstract: The present invention is directed to a composition comprising (a) cabazitaxel and (b) sulfobutyl ether beta cyclodextrin. Such composition exhibits unexpectedly desirable stability in aqueous media, permitting therapeutic dosages of the drug to be administered without the use of either ethanol or surfactants.

Abstract: A view schema is generated from a view definition, wherein the view schema includes one or more relational views that are created by translating one or more object queries in the view definition into one or more relational queries. A report design schema is generated from the view definition by: creating one or more report tables that correspond to the one or more relational views of the view schema and extending the one or more report tables with one or more primary key constraints and one or more foreign key constraints. A reporting model is generated by reverse engineering the report design schema, wherein the reporting model includes the one or more primary key constraints and the one or more foreign key constraints. A report is generated using the reporting model, wherein the report includes the one or more primary key constraints and the one or more foreign key constraints.

Abstract: A view schema is generated from a view definition, wherein the view schema includes one or more relational views that are created by translating one or more object queries in the view definition into one or more relational queries. A report design schema is generated from the view definition by: creating one or more report tables that correspond to the one or more relational views of the view schema and extending the one or more report tables with one or more primary key constraints and one or more foreign key constraints. A reporting model is generated by reverse engineering the report design schema, wherein the reporting model includes the one or more primary key constraints and the one or more foreign key constraints. A report is generated using the reporting model, wherein the report includes the one or more primary key constraints and the one or more foreign key constraints.

Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible rapamycin composition comprising a specific mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers. In other aspects, the present invention is directed to a method of making the composition.

Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.

Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.

Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible rapamycin composition comprising a specific mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers. In other aspects, the present invention is directed to a method of making the composition.

Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.

Abstract: Doxorubicin block copolymer formulations for use in preparing injectable compositions for treating cancer patients which contain lactose for solubilizing the doxorubicin and block copolymers in said formulations and methyl paraben for stabilizing these formulations, as well as a method of preparing and using these injectable compositions.

Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.

Abstract: Doxorubicin block copolymer formulations for use in preparing injectable compositions for treating cancer patients which contain lactose for solubilizing the doxorubicin and block copolymers in said formulations and methyl paraben for stabilizing these formulations, as well as a method of preparing and using these injectable compositions.

Abstract: Pharmaceutical compositions are provided which comprise a lactone form of camptothecin, or a lactone form analog thereof that is effective for controlling abnormal cell proliferation; and at least one amphiphilic block copolymer that, upon oral administration to a patient, increases oral bioavailability of the lactone form significantly more than that of a directly related carboxylate form of the camptothecin or analog thereof. Compositions are also provided that further comprise at least one bioadhesive polymer that protects a closed alpha-hydroxy lactone structure of the lactone form of camptothecin or analog thereof, and provides a controlled release of the lactone form of camptothecin or lactone form analog thereof, in GI, upon oral administration to a patient. Methods are described for the prevention and/or treatment of a condition related to abnormal cell proliferation comprising orally administering to a patient in need of thereof an effective amount of a composition of the present invention.